| Autor: |
Vasyuk YA; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.; City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia., Shkolnik EL; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.; City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia., Nesterov VV; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.; City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia., Shkolnik LD; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.; City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia., Varlan GV; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.; City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia. |
| Abstrakt: |
Anthracyclines including doxorubicin, epirubicin, daunorubicin, aclarubicin are extensively used as chemotherapeutic agents for treatment of hematological and other malignancies. In cancer therapy anthracyclines are often used in combinations with other chemotherapeutic drugs and agents for molecularly targeted therapy. Anthracyclines are effective and powerful antineoplastic drugs with wide spectrum of application but active use of preparations of this group is limited because of such side effects as cardiotoxicity, myelotoxicity, thromboembolism, alopecia, etc. Cardiotoxicity is the most severe side effect of anthracycline administration. Clinical studies have shown that it is progressive and irreversible. Therefore, early detection and prevention of anthracycline cardiotoxicity has become an important trend in cardiology. |
